Chemical Compound
16 alpha,17-[(1RS)-Butylidenebis(oxy)]-11 beta,21-dihydroxypregn-4-ene-3,20-dione; Budesonide Imp. G (EP); Budesonide USP Related Compound G; Budesonide USP RC G; 16alpha,17-[(1RS)-Butylidenebis(oxy)]-11beta,21-dihydroxypregn-4-ene-3,20-dione; (11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxy-pregn-4-ene-3,20-dione; 1,2-Dihydrobudesonide; Budesonide Related Compound G; Budesonide Impurity G
CAS Registry Number
137174-25-5
Primary record
16 alpha,17-[(1RS)-Butylidenebis(oxy)]-11 beta,21-dihydroxypregn-4-ene-3,20-dione; Budesonide Imp. G (EP); Budesonide USP Related Compound G; Budesonide USP RC G; 16alpha,17-[(1RS)-Butylidenebis(oxy)]-11beta,21-dihydroxypregn-4-ene-3,20-dione; (11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxy-pregn-4-ene-3,20-dione; 1,2-Dihydrobudesonide; Budesonide Related Compound G; Budesonide Impurity G
- 库存
- 6,427 克
- 纯度
- 98.1 %
- CAS
- 137174-25-5
化合物标识与属性
- CAS
- 137174-25-5
- PubChem CID
- 13887648
- SMILES
- CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
- Canonical SMILES
- CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
名称与同义词
- 1,2-Dihydrobudesonide
- 1,2-Dehydrobudesonide
- 137174-25-5
- 6CM8K04THA
- Budesonide EP Impurity G
- UNII-6CM8K04THA
- Budesonide Related Compound G
- 1,2-Dihydrobudesonide [USP]
- UEXJIOHTZFZGOQ-KWVAZRHASA-N
- SCHEMBL2016044
- Budesonide EP Impurity Gmonomer
- C25H36O6
- Budesonide related compound G [USP]
- 1,2-Dihydrobudesonide (Mixture of diastereomers)
- FD146154
- (1S,2S,4R,8S,9S,11S,12S,13R)-11-Hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one
- BUDESONIDE IMPURITY G [EP IMPURITY]
- CS-0166432
- 1,2-DIHYDROBUDESONIDE [USP IMPURITY]
- Budesonide EP Impurity G (Mixture of Epimer)
- BUDESONIDE RELATED COMPOUND G [USP-RS]
- H65503
- Budesonide Impurity G (1,2-Dihydro Budesonide)
- A982130
- Budesonide EP Impurity G(Mixture Of Diastereomers)
- BUDESONIDE RELATED COMPOUND G (EPIMERS) [USP IMPURITY]
- 16alpha,17-[(1RS)-Butylidenebis(oxy)]-11beta,21-dihydroxypregn-4-ene-3,20-dione (1,2-Dihydrobudesonide)
- (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregn-4-ene-3,20-dione
- Pregn-4-ene-3,20-dione, 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11beta,16alpha)-
- (11.BETA.,16.ALPHA.)-16,17-(BUTYLIDENEBIS(OXY))-11,21-DIHYDROXYPREGN-4-ENE-3,20-DIONE
- (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.0,.0,.0,icos-17-en-16-one
- (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-6b-Glycoloyl-5-hydroxy-4a,6a-dimethyl-8-propyl-3,4,4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-tetradecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]-dioxol-2-one
- (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-1,2,5,6,6a,6b,7,8,8a,8b,11a,12,12a,12b-tetradecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one
- (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-5,6,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one (Budesonide Impurity
- (6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-5,6,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2,1:4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one
- 16 alpha,17-[(1RS)-Butylidenebis(oxy)]-11 beta,21-dihydroxypregn-4-ene-3,20-dione; Budesonide Imp. G (EP); Budesonide USP Related Compound G; Budesonide USP RC G; 16alpha,17-[(1RS)-Butylidenebis(oxy)]-11beta,21-dihydroxypregn-4-ene-3,20-dione; (11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxy-pregn-4-ene-3,20-dione; 1,2-Dihydrobudesonide; Budesonide Related Compound G; Budesonide Impurity G
- PREGN-4-ENE-3,20-DIONE, 16,17-(BUTYLIDENEBIS(OXY))-11,21-DIHYDROXY-, (11.BETA.,16.ALPHA.)-